Key result
Novel nucleoside analogue LAVR-289 demonstrates broad in vitro and ex vivo efficacy against herpesviruses.
Why the study?
Human herpesviruses can trigger life-threatening infections in immunocompromised patients, but broad-spectrum inhibitors of herpesvirus infections are still lacking.
Does LAVR-289 inhibit herpesvirus infections in vitro and ex vivo?
Does LAVR-289 inhibit herpesvirus infections in vitro and ex vivo?
LAVR-289 is a novel acyclic nucleoside analogue with broad-spectrum in vitro and ex vivo activity against herpesviruses, poxviruses, and adenoviruses.
Supports further preclinical development of LAVR-289; leaves open clinical translation for herpesvirus infections.
Human herpesviruses are large dsDNA viruses that primarily cause opportunistic infections in healthy adults but can trigger life-threatening infections in immunocompromised patients. Previously, antivirals have been developed against a variety of herpesviruses; these include acyclovir for herpes simplex viruses (HSV1 and 2) and ganciclovir and letermovir for human cytomegalovirus (hCMV). However, broad-spectrum inhibitors of herpesvirus infections are still lacking. Here we report the efficacy of LAVR-289, a new acyclic nucleoside analogue, on a broad range of herpesviruses of human and animal origin. LAVR-289 displays nanomolar efficacy in vitro, is active on viral strains resistant to gold-standard antivirals and is efficacious ex vivo on reconstituted human skin infected with HSV1. In addition, the activity of LAVR-289 against poxviruses and adenoviruses is an indication of its potential for the management of opportunistic virus infections in immunocompromised patients.
No takes yet. Share an insight, caveat, or question.
Kappler‐Gratias et al. (2025) studied Herpesvirus infections. LAVR-289 was evaluated on In vitro and ex vivo efficacy against herpesviruses. LAVR-289, a new acyclic nucleoside analogue, displayed nanomolar efficacy in vitro against a broad range of herpesviruses and was efficacious ex vivo on reconstituted human skin infected with HSV1.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: